ASP3550
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostatic Neoplasms
Conditions
Prostatic Neoplasms
Trial Timeline
Oct 1, 2007 → Oct 1, 2009
NCT ID
NCT00568516About ASP3550
ASP3550 is a phase 2 stage product being developed by Astellas Pharma for Prostatic Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00568516. Target conditions include Prostatic Neoplasms.
What happened to similar drugs?
15 of 20 similar drugs in Prostatic Neoplasms were approved
Approved (15) Terminated (0) Active (5)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00568516 | Phase 2 | Completed |
Competing Products
20 competing products in Prostatic Neoplasms